MedTrace Logo

Molecular Effects of a Multi-carotenoids (MCS) New Agent on Prostate Cancer Chemoprevention

NCT02426216 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2015-10-27

No results posted yet for this study

Summary

This is to prospectively investigate whether the chemopreventive agent, MCS, may favorably alter biomarker expression, whether serum carotenoids levels are associated with biomarkers levels, and whether the alterations of biomarker expression may reflect the cancer risk as shown by cancer incidence at the end of the clinical trial.

Conditions

Sponsors & Collaborators

  • Health Ever Bio-Tech Co., Ltd.

    collaborator INDUSTRY

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Yeong-Shiau Pu · National Taiwan University Hospital

Eligibility

Min Age
50 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2018-07-31
Completion
2018-07-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02426216 on ClinicalTrials.gov